Search
Now showing items 1-10 of 15
SARS-CoV-2 and Multiple Sclerosis: Not all immune depleting DMTs are equal or bad.
(Wiley Online, 2020-05-08)
A major concern during the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic1 is the use of immunosuppressive therapies for the treatment of multiple sclerosis (MS) due to an increased risk of ...
Cladribine to halt deterioration in people with advanced multiple sclerosis (CHARIOTMS)
(2020-12)
Meeting abstract P0196 from MSVirtual 2020 – 8th Joint ACTRIMS-ECTRIMS Meeting, September 11-13, 2020
The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.
(2020-06-08)
OBJECTIVE: Ocrelizumab inhibits relapsing multiple sclerosis when administered every six months. Based on potential similar memory B cell depletion mechanisms with cladribine and alemtuzumab, we hypothesised that CD20-depletion ...